Q32 Bio (QTTB) Net Income towards Common Stockholders (2017 - 2026)
Q32 Bio's quarterly Net Income towards Common Stockholders came in at -$7.6 million in Q1 2026, up 31.02% year-on-year from -$5.8 million in Q1 2025, and down 127.23% quarter-over-quarter from $27.9 million in Q4 2025.
Q32 Bio has reported Net Income towards Common Stockholders for 10 years, with the latest figure at -$7.6 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 31.02% year-over-year to -$7.6 million; the trailing twelve-month figure through Mar 2026 stood at $3.5 million (up 128.47% YoY), and the FY2025 full-year result was $29821.0, up 146.94% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$7.6 million, down from $27.9 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $92.7 million in Q1 2022, with the low at -$34.6 million in Q4 2022.
- Average Net Income towards Common Stockholders over 5 years is -$540026.8, with a median of -$7.6 million recorded in 2026.
- Year-over-year, Net Income towards Common Stockholders jumped 8735.88% in 2022 and slumped 1172.01% in 2025.
- Tracing QTTB's Net Income towards Common Stockholders over 5 years: stood at -$34.6 million in 2022, then surged by 177.01% to $26.6 million in 2023, then climbed by 25.76% to $33.5 million in 2024, then retreated by 16.55% to $27.9 million in 2025, then slumped by 127.23% to -$7.6 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$7.6 million (Q1 2026), $27.9 million (Q4 2025), and -$7.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 2.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Q32 Bio | 162.94 Mn | 112.19 Mn | - | -7.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.61 Mn |
| Dec 31, 2025 | 27.94 Mn |
| Sep 30, 2025 | -7.39 Mn |
| Jun 30, 2025 | -9.49 Mn |
| Mar 31, 2025 | -11.03 Mn |
| Dec 31, 2024 | 33.48 Mn |
| Sep 30, 2024 | -17.60 Mn |
| Jun 30, 2024 | -16.98 Mn |
| Mar 31, 2024 | 1.03 Mn |
| Dec 31, 2023 | 26.62 Mn |
| Sep 30, 2023 | -14.03 Mn |
| Jun 30, 2023 | -5.81 Mn |
| Mar 31, 2023 | -6.84 Mn |
| Dec 31, 2022 | -34.57 Mn |
| Sep 30, 2022 | -31.64 Mn |
| Jun 30, 2022 | -27.94 Mn |
| Mar 31, 2022 | 92.66 Mn |
| Dec 31, 2021 | -33.58 Mn |
| Sep 30, 2021 | -30.61 Mn |
| Jun 30, 2021 | -30.50 Mn |
| Mar 31, 2021 | -1.07 Mn |
| Dec 31, 2020 | -29.79 Mn |
| Sep 30, 2020 | -28.23 Mn |
| Jun 30, 2020 | -35.34 Mn |
| Mar 31, 2020 | -35.33 Mn |
| Dec 31, 2019 | -24.17 Mn |
| Sep 30, 2019 | -29.63 Mn |
| Jun 30, 2019 | -26.27 Mn |
| Mar 31, 2019 | -23.85 Mn |
| Dec 31, 2018 | -18.79 Mn |
| Sep 30, 2018 | -14.15 Mn |
| Jun 30, 2018 | -12.43 Mn |
| Mar 31, 2018 | -10.22 Mn |
| Dec 31, 2017 | -11.91 Mn |
| Sep 30, 2017 | -6.53 Mn |
| Jun 30, 2017 | -6.00 Mn |
| Mar 31, 2017 | -4.68 Mn |